Wang, Alex Z.Lebastchi, Amir H.O'Connor, Luke P.Ahdoot, MichaelMehralivand, SherifYerram, NitinTaneja, Samir S.George, Arvin K.Sanchez-Salas, RafaelWard, John F.del Pilar Laguna Pes, Mariade la Rosette, Jean J. M. C. H.Pinto, Peter A.2021-10-152021-10-152021Wang, A. Z., Lebastchi, A. H., O'Connor, L. P., Ahdoot, M., Mehralivand, S., Yerram, N. ... Pinto, P. A. (2021). Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: Current perspective and ongoing trials. World Journal of Urology, 39(3), 729-739. https://dx.doi.org/10.1007/s00345-020-03525-00724-49831433-8726https://dx.doi.org/10.1007/s00345-020-03525-0https://hdl.handle.net/20.500.12511/8457Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical "middle ground" in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.eninfo:eu-repo/semantics/embargoedAccessFocal TherapyMRIProstate CancerArticle39372973910.1007/s00345-020-03525-0Q1Q1